Inventia Healthcare Limited — Telmisartan Exporter Profile
Indian Pharmaceutical Exporter · #9 for Telmisartan · $5.3M export value · DGFT Verified
Inventia Healthcare Limited is the #9 Indian exporter of Telmisartan with $5.3M in export value and 197 verified shipments. Inventia Healthcare Limited holds a 0.0% market share in Telmisartan exports across 8 countries. The company exports 11 pharmaceutical products worth $36.5M across 6 therapeutic categories.
Inventia Healthcare Limited — Telmisartan Export Profile: Buyers & Destinations
Where Does Inventia Healthcare Limited Export Telmisartan?
| Country | Value | Shipments | Share |
|---|---|---|---|
| UNITED STATES | $4.2M | 155 | 89.3% |
| UNITED ARAB EMIRATES | $203.6K | 19 | 4.3% |
| PHILIPPINES | $106.9K | 11 | 2.3% |
| NIGERIA | $62.5K | 3 | 1.3% |
| VIETNAM | $50.0K | 2 | 1.1% |
| ZIMBABWE | $34.2K | 2 | 0.7% |
| THAILAND | $25.7K | 2 | 0.5% |
| MYANMAR | $24.1K | 3 | 0.5% |
Inventia Healthcare Limited exports Telmisartan to 8 countries. The largest destination is UNITED STATES accounting for 89.3% of Inventia Healthcare Limited's Telmisartan shipments, followed by UNITED ARAB EMIRATES (4.3%) and PHILIPPINES (2.3%). These destinations reflect Inventia Healthcare Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Telmisartan from Inventia Healthcare Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| ASCEND LABORATORIES LLC | UNITED STATES | $2.0M | 68 |
| ASCEND LABORATORIES LLC, | UNITED STATES | $1.2M | 40 |
| ASCEND LABORATORIES,LLC | UNITED STATES | $852.5K | 34 |
| ASCEND LABORATORIES LLC.,., | UNITED STATES | $151.7K | 13 |
| NEW COUNTRY HEALTHCARE HEAD OFFICE | UNITED ARAB EMIRATES | $143.5K | 10 |
| TO THE ORDER OF | NIGERIA | $62.5K | 3 |
| ADCAN PHARMA LLC | UNITED ARAB EMIRATES | $60.0K | 9 |
| THE CATHAY YSS DISTRIBUTORS CO., IN | PHILIPPINES | $50.6K | 5 |
| CENTRAL PHARMACEUTICAL CPC1 JSC, | VIETNAM | $50.0K | 2 |
| OCTELLE CO., LTD | MYANMAR | $49.8K | 5 |
Inventia Healthcare Limited supplies Telmisartan to 13 buyers globally. The largest buyer is ASCEND LABORATORIES LLC (UNITED STATES), followed by ASCEND LABORATORIES LLC, (UNITED STATES) and ASCEND LABORATORIES,LLC (UNITED STATES). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Telmisartan Export Value and How Much Does Inventia Healthcare Limited Contribute?
India exported $172.2M worth of Telmisartan through 11,086 shipments from 413 suppliers to 132 countries, serving 1,116 buyers globally. Inventia Healthcare Limited contributes $5.3M to this total, accounting for 0.0% of India's Telmisartan exports. Inventia Healthcare Limited ships Telmisartan to 8 countries through 13 buyers.
What Is the Average Shipment Value for Inventia Healthcare Limited's Telmisartan Exports?
Inventia Healthcare Limited's average Telmisartan shipment value is $26.8K per consignment, based on 197 shipments totaling $5.3M. The largest destination is UNITED STATES (89.3% of Inventia Healthcare Limited's Telmisartan exports).
How Does Inventia Healthcare Limited Compare to Other Indian Telmisartan Exporters?
Inventia Healthcare Limited ranks #9 among 413 Indian Telmisartan exporters with a 0.0% market share. The top 3 exporters are CIPLA LIMITED ($81.0M), INTAS PHARMACEUTICALS LIMITED ($15.5M), MYLAN LABORATORIES LIMITED ($12.0M). Inventia Healthcare Limited processed 197 shipments to 8 destination countries.
What Telmisartan Formulations Does Inventia Healthcare Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| TELMISARTAN TABLETS USP 80 MG 30S NDC 6 | $581.6K | 14 |
| TELMISARTAN TABLETS USP 40 MG 30S NDC 6 | $233.7K | 7 |
| TELMISARTAN TABLETS USP 40 MG 30'S (EACHTABLET CONTAIN TELMISARTAN TABLETS USP40MG) | $209.7K | 6 |
| Telmisartan Tablets USP 80 mg 30'S NDC 6 | $200.0K | 4 |
| TELMISARTAN TABLETS USP 80 MG (30'S) (EACH TABLET CONTAIN TELMISARTAN TABLETS USP 80MG) | $192.8K | 5 |
| Telmisartan Tablets USP 40 mg 30'S NDC 6 | $112.4K | 4 |
| TELMISARTAN TABLETS USP 80 MG 30'S NDC NO.67877-484-30 (INV.QTY 94428 BOTTLES= NOS) | $93.5K | 3 |
| TELMISARTAN TABLETS USP 80 MG 30'S NDC 6 | $82.0K | 2 |
| TELMISARTAN TABLETS USP 20 MG (30'S) (EACH TABLET CONTAIN TELMISARTAN TABLETS USP 20MG) | $81.2K | 4 |
| Telmisartan Tablets USP 20 mg (30'S) NDC | $80.9K | 4 |
Inventia Healthcare Limited exports 111 distinct Telmisartan formulations including tablets, capsules, syrups, and combination drugs. The top formulation is TELMISARTAN TABLETS USP 80 MG 30S NDC 6 with 14 shipments worth $581.6K. Notable combination products include fixed-dose combinations with other active ingredients, meeting diverse global regulatory requirements.
Regulatory Requirements: Exporting Telmisartan to Key Markets
What Inventia Healthcare Limited must comply with to export Telmisartan to its top destination countries
United States — FDA
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Timeline: 10–18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Inventia Healthcare Limited Compare to Nearest Telmisartan Exporters?
Exporters ranked immediately above and below #9 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 7 | MICRO LABS LIMITED | $8.9M | 659 | 23 | $13.6K |
| 8 | MSN LABORATORIES PRIVATE LIMITED | $7.1M | 619 | 23 | $11.5K |
| 9 | INVENTIA HEALTHCARE LIMITED ★ | $5.3M | 197 | 8 | $26.8K |
| 11 | TORRENT PHARMACEUTICALS LTD | $3.7M | 98 | 7 | $37.7K |
| 12 | TEVAPHARM INDIA PRIVATE LIMITED | $3.3M | 93 | 3 | $35.3K |
Inventia Healthcare Limited ranks #9 among 413 Indian Telmisartan exporters. Average shipment value of $26.8K compared to the market average of $416.8K. The closest competitors by value are MICRO LABS LIMITED and MSN LABORATORIES PRIVATE LIMITED.
Which Indian Ports Ship Telmisartan Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR CARGO ACC (INBOM4) | 1,766 | 15.9% |
| SAHAR AIR | 1,729 | 15.6% |
| DELHI AIR CARGO ACC (INDEL4) | 1,003 | 9.0% |
| NHAVA SHEVA SEA (INNSA1) | 755 | 6.8% |
| DELHI AIR | 623 | 5.6% |
| AHEMDABAD AIR | 402 | 3.6% |
| Bombay Air | 396 | 3.6% |
| JNPT | 377 | 3.4% |
What Other Cardiovascular Products Does Inventia Healthcare Limited Export?
Inventia Healthcare Limited also exports these cardiovascular products. Each links to the detailed product page.
Geopolitical & Trade Policy Impact on Inventia Healthcare Limited's Telmisartan Exports
Inventia Healthcare's extensive export operations are currently navigating a complex geopolitical landscape that presents both challenges and opportunities. The ongoing Israel-Iran tensions have led to disruptions in Red Sea shipping routes, resulting in increased freight costs and extended transit times. These logistical challenges are particularly impactful for time-sensitive pharmaceutical shipments, necessitating strategic adjustments in supply chain management to mitigate potential delays and cost escalations. (pharmaceuticalcommerce.com)
In the United States, recent tariff implementations have introduced additional complexities for Indian pharmaceutical exporters. The imposition of tariffs on a broad range of imports, including pharmaceuticals, has raised concerns about cost competitiveness and market access. Companies like Inventia must navigate these policy shifts by exploring alternative markets and enhancing operational efficiencies to maintain their competitive edge. (apnews.com)
Conversely, the European Union's stringent regulatory frameworks, such as the Falsified Medicines Directive, necessitate rigorous compliance measures. While these regulations impose additional operational requirements, they also present an opportunity for companies with robust quality systems to differentiate themselves. Inventia's adherence to international quality standards positions it favorably to meet these regulatory demands and strengthen its presence in the European market.
Inventia Healthcare Limited — Regulatory Compliance & Quality Standards
The global pharmaceutical industry is witnessing heightened regulatory scrutiny, with agencies like the U.S. FDA and the European Medicines Agency intensifying their focus on manufacturing practices and product quality. For Indian exporters, this translates into the necessity for stringent compliance with Good Manufacturing Practices (GMP) and other regulatory standards.
Inventia Healthcare's manufacturing facility in Ambernath and its research and development center in Thane are accredited by the U.S. FDA, U.K. MHRA, and other stringent regulatory authorities. This compliance underscores the company's commitment to maintaining high-quality standards, facilitating access to both emerging and regulated markets. (platinumequity.com)
However, the broader Indian pharmaceutical sector faces challenges related to quality assurance, with instances of regulatory non-compliance affecting the industry's reputation. To mitigate these risks, companies like Inventia must continually invest in quality control systems, employee training, and process improvements to ensure sustained compliance and market trust.
About Inventia Healthcare Limited
Inventia Healthcare Limited exports 11 products worth $36.5M. Beyond Telmisartan, top products include Metformin, Dapagliflozin, Glimepiride, Gliclazide, Lansoprazole. View the complete Inventia Healthcare Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Telmisartan — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Telmisartan shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Inventia Healthcare Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 197 individual customs records matching Inventia Healthcare Limited exporting Telmisartan, covering 111 formulations to 8 countries via 13 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 132+ countries, 1,116+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Telmisartan Export Data from Inventia Healthcare Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Inventia Healthcare Limited's Telmisartan exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Inventia Healthcare Limited
Full Company Profile →
11 products · $36.5M total trade · 6 categories
Telmisartan Stats
Company Overview
Top Products by Inventia Healthcare Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Inventia Healthcare Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Telmisartan. For current shipment-level data, contact TransData Nexus.